Clinical trial
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
NCT00346255 is registered in ClinicalTrials.gov with ImmunoGen, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
- Lead sponsor
- ImmunoGen, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 30, 2005
- Completion date
- March 31, 2011
- Enrollment
- 37 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.